Lawrence Korngut
Investigator
Neuromuscular Neurologist, Professor, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary
NMD4C Involvement: Pillar 2: Clinical Research, Theme 5: Open Science
Email LawrenceBiography
Dr. Lawrence Korngut is a neurologist, clinical neurophysiologist and former Director of the Calgary Neuromuscular Program and the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the National Principal Investigator of the Canadian Neuromuscular Disease Registry that now includes 48 participating clinics and over the past ten years has recruited over 5500 patients.
Dr. Korngut completed his undergraduate degree in Life Sciences at Queen’s University (Kingston, Canada), medical school and neurology residency at Western University (London, Canada), neuromuscular clinical and research fellowship and Masters of Science in Clinical Epidemiology at the University of Calgary, Alberta, Canada. He serves as the Director of Innovation and Commercialization at the Hotchkiss Brain Institute.
Within NMD4C Dr. Korngut will bring in his experience of Canadian networking in CAN-NMD and participates in the network’s work in trial capacity building.
Recent Publications
Voermans, NC, Statland, JM, Hayward, LJ, Rosenbohm, A, López de Munain, A, Sacconi, S et al.. A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. J Neuromuscul Dis. 2026. 22143602261419558 PMID:41649965
Schellenberg, KL, Caspar-Bell, G, Ellis, C, Johnston, W, King, A, King, M et al.. [Not Available]. CMAJ. 2026.198 (3)E96-E111 PMID:41587800
Rudnicki, SA, Giacomelli, E, Herder, K, Ingre, C, Kupfer, S, Malik, FI et al.. The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS. Muscle Nerve. 2026. PMID:41553108
Jacob, SM, Son, B, Bagheri, S, Lee, S, Leckie, J, Chohan, B et al.. The Oral Microbiome in Amyotrophic Lateral Sclerosis Shows Differentially Abundant Organisms in Limb Versus Bulbar Onset Disease: A Binational Study. J Clin Neurol. 2026.22 (1)66-75 PMID:41517814
Kools, J, Korngut, L, Petrillo Ballantyne, J, Roozen, I, de Haas, R, Hill, A et al.. A toolkit for new facioscapulohumeral muscular dystrophy trial sites. J Neuromuscul Dis. 2025. 22143602251399244 PMID:41451875
See more on PubMed